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A subset of breast cancer patients benefits from preoperative bevacizumab and chemotherapy, but 
validated predictive biomarkers are lacking. Here, we aimed to evaluate tissue‑based angiogenesis 
markers for potential predictive value regarding response to neoadjuvant bevacizumab treatment 
in breast cancer. In this randomized 1:1 phase II clinical trial, 132 patients with large or locally 
advanced HER2‑negative tumors received chemotherapy ± bevacizumab. Dual Factor VIII/Ki‑67 
immunohistochemical staining was performed on core needle biopsies at baseline and week 12. 
Microvessel density (MVD), proliferative microvessel density (pMVD; Factor VIII/Ki‑67 co‑expression), 
glomeruloid microvascular proliferation (GMP), and a gene expression angiogenesis signature score, 
were studied in relation to pathologic complete response (pCR), clinico‑pathologic features and 
intrinsic molecular subtype. We found that high baseline MVD (by median) significantly predicted 
pCR in the bevacizumab‑arm (odds ratio 4.9, P = 0.012). High pMVD, presence of GMP, and the 
angiogenesis signature score did not predict pCR, but were associated with basal‑like (P ≤ 0.009) 
and triple negative phenotypes (P ≤ 0.041). pMVD and GMP did also associate with high‑grade 
tumors (P ≤ 0.048). To conclude, high baseline MVD significantly predicted response to bevacizumab 
treatment. In contrast, pMVD, GMP, and the angiogenesis signature score, did not predict response, 
but associated with aggressive tumor features, including basal‑like and triple‑negative phenotypes.
Angiogenesis, new blood vessel growth from the existing  vasculature1,2, is a hallmark of cancer and promotes 
tumor progression and  metastasis1,3. Bevacizumab is a humanized monoclonal antibody against vascular 
endothelial growth factor A (VEGF-A), a key factor in this  process4. It was approved by the FDA in  20084 for 
use in metastatic HER2-negative breast cancer in combination with  paclitaxel5, although later studies reported 
only small improvements in progression-free  survival6,7 and no effect on overall  survival5–7. Consequently, the 
FDA-approval was withdrawn in  20114. In the preoperative setting, however, bevacizumab in combination with 
chemotherapy has shown improved pathologic complete response (pCR) in several clinical trials in HER2-
negative breast  cancer8–12, with improved overall survival in one  study13. Currently, although bevacizumab is not 
routinely used in breast cancer, it has an important clinical role in several other solid cancer  types14. Also, new 
combinations including bevacizumab and immune check point inhibitors show promising  results15,16. A major 
challenge concerning bevacizumab treatment is the lack of biomarkers for patient  stratification17.
In tumor tissue, microvessel density (MVD) has shown prognostic value in breast  cancer18,19. As a novel 
marker of activated angiogenesis, proliferation of microvessels, pMVD (proliferative microvessel density) has 
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shown even stronger association with prognosis compared with  MVD20. Other tissue markers of angiogenesis 
are the “vascular nest” phenotype of glomeruloid microvascular proliferation (GMP)21, assumed to be VEGF-A 
 associated22, as well as a microarray-based 32-gene angiogenesis  signature23,24. Presence of GMP has been associ-
ated with reduced breast cancer survival and lack of response to  chemotherapy25,26.
Here, in a phase II clinical trial, patients with locally advanced (HER2-negative) or large breast cancers 
(≥ 2.5 cm) were randomized to receive chemotherapy ± bevacizumab. The purpose of the study was to evaluate 
whether tissue-based markers of angiogenesis (MVD, pMVD, GMP, 32-gene signature) could predict response 
to bevacizumab treatment and provide a basis for patient stratification.
Results
High microvessel density predicts pCR in bevacizumab treated patients. The NeoAva study 
design is presented in Fig. 1. As previously  reported27, pCR in breast and axillary lymph nodes was seen in 15 
patients (23%) in the bevacizumab-arm, and in 8 patients (12%) in the chemotherapy only-arm (Fisher’s exact 
test, P = 0.17). Among ER positive tumors, 11 patients (20%) responded in the bevacizumab-arm, compared with 
only 3 (5%) in the chemotherapy only-arm (Fisher’s exact test, P = 0.02). No significant difference in response 
was seen between the two treatment arms for ER negative patients.
Microvessels were evaluated in 128 patients at baseline (64 in each treatment arm, four excluded) (Fig. 2). 
When selecting the three HPFs (high power fields) with the highest number of vessels, median MVD was 112.1 
vessels/mm2 (mean 120.8, range 52.4–267.9), and median pMVD was 5.8 vessels/mm2 (mean 6.4, range 0.0–20.4). 
MVD and pMVD were dichotomized by median values, and no significant differences were seen between the 
two treatment arms at baseline (Pearson’s chi-square test).
High MVD (≥ median) was significantly associated with pCR in the bevacizumab arm (OR, odds ratio, 
4.9, P = 0.012), but not in the chemotherapy only-arm (Table 1 and Fig. 3). In the subgroup of patients treated 
with paclitaxel and bi-weekly bevacizumab, 14 of 45 patients  responded28. High MVD was seen in 10 of the 
14 responders in the paclitaxel subgroup (OR of 5.0; P = 0.018; 1 case with missing MVD-status). The sub-
group receiving docetaxel and tri-weekly bevacizumab was too small for a similar comparison (1 of 21 patients 
responded). When analysing the subgroup of patients receiving paclitaxel in the chemotherapy only-arm, no 
Figure 1.  The NeoAva study design. Patients included in the study were randomized to receive chemotherapy 
with or without bevacizumab.
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association between MVD and pCR was found (n = 47, 6 responders, 1 case with missing MVD status). In con-
trast, pMVD was not associated with response in any of the treatment arms; this was also found for the paclitaxel 
subgroup (P = 0.7). At baseline, GMP was present in 14 of 130 patients evaluated (11%), seven in each arm, with 
no association with treatment response (Table 1 and Fig. 3). The 32-gene angiogenesis signature score was not 
significantly associated with response in any of the treatment arms (Fig. 3).
Stratified by ER (estrogen receptor) status, high MVD tended to associate with response in the bevacizumab-
arm in the ER positive subgroup. High MVD was seen in 7 of the 10 responders (70%) in ER-positive bevaci-
zumab-treated patients, compared with high MVD seen in 15 of 42 (38%) non-responders (OR 4.2, P = 0.075, 
Fisher’s exact test; 2 cases with missing MVD-status). No significant associations were seen among ER negative 
cases, or in the chemotherapy only-arm. With the low number of patients included in these groups, and the few 
Figure 2.  Factor VIII/Ki-67 dual immunohistochemical staining. Combined immunohistochemical staining of 
Factor VIII (red) and Ki-67 (blue), 400×. (A) Factor VIII positive, non-proliferative microvessels (MVD), (B) 
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Table 1.  MVD, pMVD, GMP according to pathologic complete response (pCR). All patients: MVD and 
pMVD analyses: Pathologic complete response: N = 22; bevacizumab-arm: N = 14, chemotherapy only-
arm, N = 8. GMP analyses: Pathologic complete response: N = 21; bevacizumab-arm: N = 13, chemotherapy 
only-arm, N = 8. MVD and pMVD; N = 128 (64 in each arm), GMP: N = 130 (bevacizumab-arm, N = 64, 
chemotherapy only-arm, N = 66). MVD microvessel density, pMVD proliferative microvessel density, GMP 
glomeruloid microvascular proliferation, N number of patients, OR odds ratio, CI confidence interval, P p 
values by Pearson’s chi-square test. a Fisher’s exact test.
MVD, N = 128 pMVD, N = 128 GMP, N = 130
≥ Median ≥ Median Present
N % OR 95% CI P N % OR 95% CI P N % OR 95% CI P
All patients
Pathologic response
Not complete 48 45 Ref 60 57 Ref 11 10 Ref
Complete 17 77 4.1 1.4–12.0 .006 12 55 0.9 0.4–2.3 NS 3 14 1.5 0.4–5.9 NSa
Bevacizumab-arm
Pathologic response
Not complete 17 34 Ref 26 52 Ref 6 12 Ref
Complete 10 71 4.9 1.3–17.8 .012 6 43 0.7 0.2–2.3 NS 1 8 0.6 0.1–5.7 NSa
Chemotherapy only-arm
Pathologic response
Not complete 31 55 Ref 34 61 Ref 5 9 Ref
Complete 7 88 5.6 0.7–49.0 NSa 6 75 1.9 0.4–10.5 NSa 2 25 3.5 0.6–22.3 NSa
Figure 3.  pCR according to MVD, pMVD, GMP and the 32-gene angiogenesis signature score. Each bar 
represents number of patients by high and low biomarker for all patients, the bevacizumab-arm (Bev + Chemo), 
and the chemotherapy only-arm (Chemo). pCR (pathologic complete response) rates are presented by 
%-estimates and indicated by dark blue color. P values by Pearson’s chi-square (χ2) test or Fisher’s exact test. 
aFisher’s exact test. MVD microvessel density, pMVD proliferative microvessel density, A.S. angiogenesis 
signature score. Median as cut-off value.
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responders observed, these latter analyses should be interpreted with care. pMVD and GMP did not predict 
response in either arms when stratifying for ER status (data not shown).
Angiogenesis markers pMVD, GMP and a 32‑gene signature associate with aggressive tumor 
features. Increased vascular proliferation (pMVD) was significantly associated with high histologic grade 
(OR 2.6, P = 0.048), negative ER (OR 5.9, P = 0.003) and PR (progesterone receptor) status (OR 2.2, P = 0.032), 
and strongly associated with the triple negative phenotype (OR 9.0, P = 0.001) (Table 2). Further, pMVD differed 
between the intrinsic molecular subtypes (Kruskal–Wallis test, P < 0.0005) (Fig. 4), with high values seen sig-
nificantly more often in the basal-like subgroup compared with other categories (OR 20.1, P = 0.001) (Table 2). 
Similar findings were seen for GMP, with a significant and strong association with high histologic grade (OR 
6.2, P = 0.003), the triple negative phenotype (OR 3.7, P = 0.041), and a tendency to associate with ER negative 
tumors (OR 3.5, P = 0.051). Most GMP positive tumors (9 of 14 cases) had HER2-enriched or basal-like phe-
notypes, and the association with the basal-like group was highly significant when compared with the other 
subgroups (OR 5.4, P = 0.009).
Whereas high MVD was associated with larger tumors (OR 2.4, P = 0.026, for T3 vs T2 tumors), and also 
significant for T3 and T4 tumors combined versus T2 (data not shown), there were no associations with any other 
clinico-pathologic features, including histologic grade, hormone receptor status (ER/PR), or the triple negative 
phenotype (Table 2). MVD was not associated with intrinsic molecular subtypes by PAM50 (Kruskal–Wallis, 
continuous; Fig. 4; or Pearson’s chi-square tests, dichotomous), although there was a trend for higher MVD in 
the basal-like group (OR 2.7, P = 0.056, Table 2).
The 32-gene angiogenesis signature score differed across molecular subtypes (P < 0.0005) (Fig. 4), with highest 
values in the basal-like subtype, and also high expression in the HER2-enriched category. The pattern was similar 
to the pMVD distribution (by immunohistochemistry) across intrinsic molecular subtypes, and the signature 
score was significantly correlated with pMVD values (Spearman’s ρ = 0.30, P = 0.001). Also, high signature score 
(by median) significantly associated with ER negative (OR 5.3, P = 0.002), triple negative (OR 4.9, P = 0.004) and 
basal-like tumors (OR 27.8, P < 0.0005), but not with PR status, tumor size or histologic grade (data not shown).
Table 2.  MVD, pMVD, GMP by clinico-pathologic variables and molecular subtypes of breast cancer. Tumor 
stage: T4 tumors were excluded from the analyses. T2: 2,5- < 5 cm and T3: ≥ 5 cm in diameter. MVD and 
pMVD; N = 128, GMP; N = 130. Missing data: histologic grade: N = 8 (MVD and pMVD analyses) N = 7 (GMP 
analyses); molecular subtype: N = 1. MVD microvessel density, pMVD proliferative microvessel density, GMP 
glomeruloid microvascular proliferation, N number of patients, OR odds ratio, CI confidence interval, P p 
values by Pearson’s chi-square test. a Fisher’s exact test.
MVD, N = 128 pMVD, N = 128 GMP, N = 130
≥ Median ≥ Median Present
N % OR 95% CI P N % OR 95% CI P N % OR 95% CI P
Estrogen receptor
Positive 53 50 Ref 54 51 Ref 9 8 Ref
Negative 12 57 1.4 0.5–3.5 NS 18 86 5.9 1.6–21.2 0.003 5 24 3.5 1.0–11.7 0.051a
Progesterone receptor
Positive 37 47 Ref 38 49 Ref 6 8 Ref
Negative 28 56 1.4 0.7–2.9 NS 34 68 2.2 1.1–4.7 0.032 8 16 2.3 0.7–7.0 NS
Triple negative
Absent 54 50 Ref 54 50 Ref 9 8 Ref
Present 11 55 1.2 0.5–3.2 NS 18 90 9.0 2.0–40.7 0.001 5 25 3.7 1.1–12.7 0.041a
Tumor stage
T2 14 37 Ref 18 47 Ref 6 16 Ref
T3 47 59 2.4 1.1–5.4 0.026 46 58 1.5 0.7–3.3 NS 4 5 0.3 0.1–1.0 0.073a
Histologic grade
1–2 45 48 Ref 49 53 Ref 6 6 Ref
3 15 56 1.3 0.6–3.2 NS 20 74 2.6 1.0–6.6 0.048 8 30 6.2 1.9–19.9 0.003a
Molecular subtype
Luminal A 25 47 20 38 2 4
Luminal B 20 50 24 60 3 8
HER2-enriched 3 33 6 67 3 33
Basal-like 14 70 19 95 6 30
Normal breast-like 2 40 NSa 2 40 < 0.0005a 0 0 0.004a
Basal-like
Absent 50 47 Ref 52 49 Ref 8 7 Ref
Present 14 70 2.7 1.0–7.4 0.056 19 95 20.1 2.6–156 < 0.0005 6 30 5.4 1.6–17.9 0.009a
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Lower values of angiogenesis markers MVD and pMVD at week 12 but with no association to 
treatment response. Median MVD and pMVD were 53.9 and 1.5 vessels/mm2 in the bevacizumab-group 
at week 12, and 87.4 and 4.4 vessels/mm2 in the chemotherapy only-group. Using matched samples, MVD and 
pMVD showed significantly lower vessel numbers at week 12 compared with the values at baseline (in both 
arms) (P < 0.0005, Wilcoxon signed rank test). The average reduction in the bevacizumab-arm for MVD and 
pMVD was 51% and 61%, respectively, compared with 32% and 45% in the chemotherapy only-arm.
When dichotomizing MVD and pMVD vessel numbers at week 12, by baseline median values, only 1 of 38 
patients in the bevacizumab-arm, and 6 of 39 patients in the chemotherapy only-arm, had high MVD, although 
this did not reach statistical significance (OR 6.7, CI 0.8–58.8, P = 0.11, Fisher’s exact test). For pMVD, 4 of 38 
patients had pMVD above baseline median in the bevacizumab arm, and 18 of 39 in the chemotherapy only-
arm (OR 7.3, CI 2.2–24.5, P = 0.001, Pearson’s chi-square test). At week 12, neither high MVD nor high pMVD 
(by baseline median values) were associated with response to treatment. pMVD at 12 weeks, but not MVD, still 
correlated with the 32-gene angiogenesis signature score estimated at 12 weeks (Spearman’s ρ = 0.34, P = 0.004); 
the angiogenesis score was not significantly different between the treatment arms at week 12 (data not shown).
The absolute difference in MVD and pMVD values from baseline to week 12 was calculated, and there was 
a trend towards patients in the bevacizumab-arm having a larger reduction in MVD (by median), than in the 
chemotherapy only-group (OR 2.3, CI 0.9–5.7, P = 0.082). For pMVD, this difference between baseline and week 
12 was not significantly different between the treatment arms. Notably, the difference in MVD and pMVD values 
between baseline and week 12 were not significantly associated with response.
Neither MVD or pMVD at week 12, nor the difference from baseline to week 12 for MVD or pMVD, were 
associated with any clinico-pathologic variables or intrinsic breast cancer subtypes (Pearson’s chi-square or 
Fisher’s exact tests; data not shown).
Figure 4.  MVD, pMVD and the 32-gene angiogenesis signature score across intrinsic molecular breast cancer 
subtypes. MVD: microvessel density; pMVD: proliferative microvessel density, and the 32-gene angiogenesis 
signature score across intrinsic molecular breast cancer subtypes. Lum: luminal; HER2: HER2-enriched, Basal: 
basal-like; Norm: normal breast-like. P-values by the Kruskal–Wallis test, and error bars with 95% confidence 
interval of the mean. Number of patients; MVD and pMVD: N = 127 (Basal: N = 20, HER2: N = 9, Lum A: N = 53, 
Lum B: N = 40, Norm: N = 5), angiogenesis signature score: N = 131 (Basal: N = 21, HER2: N = 9, Lum A: N = 55, 
Lum B: N = 40, Norm: N = 6).
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Discussion
In the neoadjuvant setting, improved pCR rates have been reported with the addition of bevacizumab to anthra-
cycline and taxane based  chemotherapy8–12. In the present study, we analysed whether tissue-based evaluation 
of angiogenesis markers MVD, pMVD, GMP and a 32-gene signature score could predict response to this treat-
ment. Notably, high baseline MVD was the only marker that showed an association to increased pCR rates in 
the bevacizumab-arm. High MVD was still significantly associated with response when selecting for patients 
receiving bi-weekly bevacizumab in combination with paclitaxel (excluding patients receiving tri-weekly beva-
cizumab in combination with docetaxel). Also, in ER-positive bevacizumab-treated patients, there was a trend 
towards association with high MVD. Similar findings, with high MVD predicting response in breast cancer, 
were reported by Tolaney et al.29, but was not found in the smaller study by Yang et al.30. However, in these two 
studies, the chemotherapy regimens differed from ours, and subgroup analyses stratifying by ER status were 
not performed. High MVD and prediction of response to bevacizumab treatment was also reported in a recent 
study of ovarian  cancer31.
We found that significantly more patients had lower pMVD values at week 12 (by baseline median) in the 
bevacizumab-arm compared with the chemotherapy only-arm. There was also a trend towards more patients 
in the bevacizumab-arm having a larger reduction in MVD from baseline to week 12. These findings are in line 
with results from preclinical models, were both pMVD and MVD were reduced after bevacizumab  treatment32.
We initially hypothesized that patients with increased numbers of proliferating microvessels would respond 
better to anti-angiogenesis treatment. However, although pMVD was significantly lower in the bevacizumab-
arm compared with the chemotherapy only-arm after 12 weeks of treatment, we found no association between 
pMVD values and response (pCR) to bevacizumab treatment in this study, neither using baseline values, week 
12 values, nor the difference from baseline to week 12. However, baseline pMVD was significantly related to 
several markers of aggressive disease, including high histologic grade as well as the triple negative and basal-like 
phenotypes, whereas this was not seen for MVD. Further, the 32-gene angiogenesis signature score based on high 
pMVD levels in our previous  study24, was not associated with response, but was correlated with tissue-based 
pMVD expression and showed similar associations as pMVD across intrinsic molecular breast cancer subtypes.
A limitation regarding analyses of tissue-based markers in the neoadjuvant setting is the small amount of 
tissue available. Core needle biopsies and not surgical specimens were examined, in contrast to previous stud-
ies in this  field18,20,24,25, possibly influencing hot-spot selection for MVD and pMVD  assessment18,20,24. Also, the 
frequency of GMP positive tumors was lower than previously  reported25. However, despite the limited amount 
of tissue available, similar associations concerning clinico-pathologic variables and intrinsic molecular subtypes 
were found for pMVD and GMP as previously  published20,25,26,33.
In summary, in this randomized phase II clinical trial of neoadjuvant chemotherapy ± bevacizumab in large 
or locally advanced HER2-negative primary breast cancer, high baseline MVD, reflecting the overall vascular 
density, was the only significant predictor of bevacizumab treatment response. Evaluation of MVD requires 
immunohistochemical staining of vessels on formalin-fixed paraffin-embedded tissues, a well-established method 
in pathology departments. Although there might be issues regarding reproducibility of vessel assessment, our 
experience is that high levels of agreement can be reached after initial training in the research setting, as sup-
ported by high inter- and intra-observer agreement in our study. However, whether MVD is a useful and robust 
clinical biomarker in relation to bevacizumab used as neoadjuvant therapy should be further validated in the 
routine setting as a potential basis for patient stratification. Other markers for activated angiogenesis, including 
pMVD, GMP, and a 32-gene signature score, did not predict response, but were all associated with aggressive 
breast cancer features including high histologic grade, basal-like and triple negative tumors.
Methods
Patients and study design. As  described27, patients with large primary breast cancer (tumor diame-
ter ≥ 2.5 cm) and locally advanced disease, previously untreated HER2-negative breast carcinomas were eligible. 
Other key inclusion criteria were WHO performance status 2, adequate hematologic and biochemical param-
eters, and no sign of metastatic disease. Additional prerequisites were normal organ function in general and 
normal left ventricular ejection fraction. Concomitant medications with anticoagulants, other than low dose 
acetylsalicylic acid (160 mg or lower) were not allowed. 138 patients were included during 2008–2012 (Oslo 
University Hospital, Oslo; St. Olav’s Hospital, Trondheim, Norway). Patients were stratified based on tumor 
size (2.5 ≤ T ≤ 5 cm, T > 5 cm) and hormone receptor status [positive for estrogen receptor (ER), progesterone 
receptor (PR), or both], and randomized 1:1 to receive chemotherapy ± bevacizumab. A block randomization 
procedure was used, and randomization was performed by the centralized research support facility at Oslo 
University Hospital (Oslo, Norway). The randomization list was not known to the personnel responsible for pro-
viding information or treatment to the patients. Six patients were excluded, leaving 66 patients in each arm for 
further analyses (Fig. 1). Clinical characteristics of included patients and adverse effects have been  published27. 
Analyses performed in this study, focusing on angiogenesis markers and treatment response, were done as part 
of exploratory analyses and did therefore not form the basis for power calculations. Written informed consent 
was obtained from all patients prior to inclusion. The study was approved by the protocol review board at Clinic 
for Cancer Therapy at Oslo University Hospital, the regional ethics committee (REK SørØst) and the Norwegian 
Medicines Agency, and carried out in accordance with the Declaration of Helsinki, International Conference 
on Harmony/Good Clinical practice. Trial Registration: http://www.clini caltr ials.gov/; identifier NCT00773695. 
Registered on October 16, 2008.
Treatment and response evaluation. The chemotherapy regimen consisted of four cycles of FEC100 
(5FU 600 mg/m2, epirubicine 100 mg/m2, and cyclophosphamide 600 mg/m2) given every third week, followed 
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by four cycles with docetaxel (100 mg/m2) every third week or 12 weekly infusions with paclitaxel 80 mg/m2. 
Bevacizumab was administered intravenously at a dose of 15 mg/kg every third week, or 10 mg/kg every other 
week in patients receiving docetaxel (n = 21) or paclitaxel (n = 45),  respectively28.
The primary end-point was pathologic complete response (pCR), defined as the absence of invasive carcinoma 
in the breast and in the axillary lymph nodes.
Immunohistochemistry. Formalin-fixed paraffin-embedded routine core needle biopsies at time of diag-
nosis, in addition to a biopsy collected before treatment start and at week 12, were available. Of the 132 patients 
in the cohort, 131 and 94 patients had available tissue at time of diagnosis, and at week 12, respectively.
Staining was done on 4–5 µm formalin-fixed paraffin-embedded standard tissue sections. Pre-treatment of 
the sections was done, i.e. pressure cooker antigen retrieval in Target Retrieval Solution pH 6.0 (Dako S1699, 
Glostrup, Denmark), and 8 min incubation with Dual Endogenous Enzyme-Blocking Reagent (Dako 2003). 
The sections were incubated for 60 min at room temperature with polyclonal rabbit anti-human Factor VIII 
related antibody (Dako A0082) diluted 1:1600 and monoclonal mouse Ki-67 antibody (Dako M7240) diluted 
1:200 in Antibody diluent (Dako S3022). Alkaline phosphatase goat anti-mouse (H + L) IgG (Southern Biotech, 
Birmingham, AL, USA) diluted 1:100 in horseradish peroxidase goat anti-rabbit EnVision (Dako K4011) was 
applied for 30 min at room temperature. Visualization of Ki-67 with Ferangi Blue™ Chromogen System (Biocare 
Medical, Concord, CA, USA, FB812S) for 15 min and of Factor VIII with AEC + Substrate-Chromogen (Dako 
K3469) for 15 min at room temperature. Counterstaining was not done. Positive and negative controls were 
included in each staining round.
Evaluation of tissue‑based angiogenesis markers. Microvessel density (MVD). As described by 
Weidner et al.18, the tissue sections were first examined at low magnifications (25× and 100×) to identify the 
most vascular areas of the invasive tumor (“hot-spots”) within the core needle biopsies. Then, vessels were 
counted in 3–10 consecutive fields, depending on amount of available tissue, at high magnification (400x, field 
size 0.23  mm2)34.
Vessels were recognized by their Factor VIII positive endothelial cells combined with their morphology. Any 
red-stained endothelial cell or cluster of endothelial cells that was clearly separate from adjacent microvessels, 
tumor cells, and other connective tissue elements, was considered a single, countable vessel. Notably, vessel 
lumens were not necessary for a structure to be defined as a vessel, but in cases with GMP or long, winding and 
branching vessels, each lumen was regarded as a single vascular unit and counted. The fields used to count vessels 
should contain at least 50% invasive tumor tissue (with exceptions for the week 12 biopsies, as discussed below), 
and vessels associated with necrotic areas or fibrotic scars were  excluded34.
Proliferative microvessel density (pMVD). pMVD is a measure of the number of microvessels containing prolif-
erating endothelial cells within the evaluated tumor area. Proliferating endothelial cells were recognized by their 
co-expression of Factor VIII and Ki-67. The same microscopic fields and vessel criteria were used for MVD and 
pMVD assessment. Ki-67 positive nuclei outside the endothelial cell layer or within the vessel lumen were not 
counted. Microvessels were regarded as proliferating when they contained one or more proliferating endothelial 
 cells34.
Evaluation of tissue biopsies at week 12. Biopsies from 94 patients were available at week 12. Of these, 46 patients 
had biopsies with ≥ 50% tumor tissue in at least three high power fields (HPFs) and 12 patients had < 50% tumor 
cells in at least three HPFs in their biopsy. In biopsies from 19 patients, no tumor cells were seen, but there were 
changes in the connective tissue consistent with chemotherapy induced tissue reaction. Vessels were counted in 
these biopsies. However, if the biopsy did not include tumor cells or tissue changes suggesting chemotherapy 
treatment reactions, patients were excluded because of uncertainty regarding the representativeness of the sam-
ple (N = 12). Also, five cases had less than three HPFs for evaluation and were excluded, leaving 77 patients for 
analyses (38 in the bevacizumab-arm and 39 in the chemotherapy only-arm).
Glomeruloid microvascular proliferation (GMP). Focal glomerulus-like aggregates of closely associated and 
multilayered Factor VIII positive endothelial cells, GMPs, were evaluated (by O.S.), as either present or  absent25. 
Lumen formation was not necessary for the glomerulus-like structures to be registered as GMP. At baseline, 130 
patients had enough tumor tissue for GMP evaluation.
Variables and cut‑off values. For MVD and pMVD, the three HPFs with highest number of vessels were selected 
for further analysis. At baseline, four patients had less than three HPFs for evaluation of MVD and pMVD, and 
were therefore excluded, leaving 128 patients, 64 in each treatment arm, for further analyses. Baseline MVD and 
pMVD were dichotomized by the median value. Cut-off by the upper quartile was also explored, but gave some-
what weaker results (data not shown). For MVD and pMVD at week 12, the baseline median values were used 
as cut-off values. Vascular proliferation Index (VPI), the ratio between the number of microvessels containing 
proliferating endothelial cells and the total number of Factor-VIII positive microvessels (pMVD/MVD), given 
as a percentage, was also analysed but gave somewhat weaker results (data not shown). The average value of all 
HPFs, and the one HPF with the highest vessel count for MVD, pMVD, and VPI, were also examined, but the 
results were similar or weaker as for the maximum of three HPFs (data not shown).
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Inter‑ and intra‑observer agreement. Before evaluating MVD, pMVD and VPI in the research series, training 
was done on a test set of 24 tissue sections (endometrial carcinoma). These were scored separately by an experi-
enced pathologist (I.M.S.). Difficulties concerning evaluation of vessels were discussed. Inter- and intra-observer 
agreements were estimated by Kappa (к) and Spearman’s rho (ρ), dichotomized by median value, and the train-
ing was not ended until both inter- and intra-observer agreements reached a satisfactory and stable value. The 
final inter- and intra-observer agreement reached Kappa values (κ) ≥ 0.7 and Spearman’s rho (ρ) > 0.8. Intra-
observer agreement for the main study, for both MVD and pMVD showed Kappa values, κ = 0.7 and Spearman’s 
ρ = 0.934.
Gene expression analysis. Gene expression profiling was performed using 40 ng total RNA and one color 
Sureprint G3 Human GE 8 × 60  k Microarrays (Agilent Technologies), as previously  described27. Molecular 
subtype determination was performed using the PAM50  algoritm35. A 32-gene expression signature based on 
differentially expressed genes in pMVD high vs low cases (by median value), originally determined in an endo-
metrial cancer  cohort24, was applied in the present data set. The angiogenesis signature score was generated by 
subtracting the sum of the expression values for the down-regulated genes from the sum of expression values for 
the up-regulated genes. The microarray data are available in the ArrayExpress database (http://www.ebi.ac.uk/
array expre ss) under accession number E-MTAB-4439.
Statistical analysis. Data were analysed using SPSS (version 22.0, IBM corp., Armonk, NY, USA). Associa-
tions between categorical variables were evaluated by Pearson’s chi-square (χ2) test or Fisher’s exact test when 
appropriate. Odds ratios (OR) and 95% confidence intervals (CI) are presented. For paired data (baseline and 
week 12 biopsies), Wilcoxon signed rank test was used. Spearman’s rank correlation test was applied when 
comparing bivariate continuous variables, and the Kruskal–Wallis test for analysing differences across intrinsic 
breast cancer subtypes.
All statistical tests were two-sided, and statistical significance was assessed at 5% level, and P values between 
5 and 10% were regarded as borderline significant.
Ethical approval and informed consent. The study was approved by the protocol review board at Clinic 
for Cancer Therapy at Oslo University Hospital, the regional ethics committee (REK SørØst) and the Norwegian 
Medicines Agency, and carried out in accordance with the Declaration of Helsinki, International Conference on 
Harmony/Good Clinical practice. Written informed consents were obtained from all patients prior to inclusion.
Data availability
The datasets generated and analysed during the current study are available from the corresponding author upon 
reasonable request. The microarray dataset supporting the conclusions of this article is available in the ArrayEx-
press database, accession number E-MTAB-4439 (http://www.ebi.ac.uk/array expre ss). The trial is registered in 
the http://www.clini caltr ials.gov/ website; identifier NCT00773695. Registered on October 16, 2008.
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